Little Green Pharma plans $22m raise to boost cannabis production and push internationally

Little Green Pharma plans $22m raise to boost cannabis production and push internationally

Medicinal cannabis cultivator and manufacturer Little Green Pharma (ASX: LGP) will use the proceeds of a planned $22 million raise to accelerate its global expansion plans and increase its manufacturing capacity.

As announced today, LGP has received firm commitments to raise approximately $22 million by way of a placement of shares.

The company, which operates an indoor cultivation facility in Western Australia, hopes to raise a further $5 million by way of a share purchase plan (SPP).

Proceeds of both the placement and the and the SPP will enable the company to accelerate sales and marketing efforts in Australia and offshore, expand its cultivation and manufacturing capacity, and provide general working capital.

At $0.65 per new share under the placement, representing a discount of 30.5 per cent to the last traded price on 4 February when the company went into a trading halt, 34 million new shares will be issued.

"We're highly encouraged by the strong support shown by new and existing shareholders for Little Green Pharma," says LGP managing director Fleta Solomon.

"I'd like to thank our existing shareholders for their continued support and would like to welcome new investors to the Little Green Pharma family.

"Little Green Pharma has gone from strength to strength, and has achieved immense growth in the last year, most recently setting new records for quarterly revenue, unit sales, and patient numbers."

LGP's raise comes hot on the heels of the news that the company was named the primary manufacturer for a trial of cannabis oil in France.

If the trial is successful, LGP will have the first mover advantage in an anticipated French market potentially worth 4 billion (AUD$6.3 billion).

The trial, to be conducted in partnership with French pharmaceutical distributor Intsel Chimos, will be the only pathway for the supply of cannabis medicines into France for the next two years.

Shares in LGP are down 14.97 per cent to $0.80 per share at 3.13pm AEDT.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Little Green Pharma finds French foothold as primary manufacturer for cannabis trial

Little Green Pharma finds French foothold as primary manufacturer for cannabis trial

Medicinal cannabis company Little Green Pharma (ASX: LGP) is toda...

Cannabis companies celebrate TGA green light for over the counter sales

Cannabis companies celebrate TGA green light for over the counter sales

Australian medicinal cannabis companies have praised the Therapeu...

Health fund backs medicinal cannabis with Little Green Pharma deal

Health fund backs medicinal cannabis with Little Green Pharma deal

Little Green Pharma (ASX: LGP) hopes a new strategic partnership ...

Australia's top 20 cannabis companies

Australia's top 20 cannabis companies

Let's not beat around the bush. The last 12 months have been ...